Sherene Loi
谢伦·洛伊
MD, PhD
Professor and Head, Translational Breast Cancer Genomics and Immunology Laboratory; Medical Oncologist, Peter MacCallum Cancer Centre彼得·麦卡勒姆癌症中心转化性乳腺癌基因组学与免疫学实验室主任、教授；肿瘤内科医生
👥Biography 个人简介
Sherene Loi, MD, PhD is Professor and Head of the Translational Breast Cancer Genomics and Immunology Laboratory at Peter MacCallum Cancer Centre, and leads a major translational research program at the University of Melbourne. She is internationally recognized as the world's foremost authority on the tumor immune microenvironment in breast cancer, having pioneered the clinical significance of tumor-infiltrating lymphocytes (TILs) as prognostic and predictive biomarkers across breast cancer subtypes. Dr. Loi demonstrated in landmark studies that high TIL counts are strongly associated with improved survival in triple-negative (TNBC) and HER2-positive breast cancer, findings later validated in multiple independent cohorts and now incorporated into breast cancer pathology reporting guidelines by the International TILs Working Group. She has also contributed pivotal translational analyses identifying TIL levels and immune gene signatures as predictors of immunotherapy benefit in TNBC, supporting the KEYNOTE-522 and IMpassion130 approval datasets. Dr. Loi received a prestigious ERC Starting Grant and an NHMRC Investigator Grant and has been elected to the Australian Academy of Health and Medical Sciences. She has published more than 200 peer-reviewed articles, is a highly cited researcher (Web of Science), and serves on the editorial boards of Nature Medicine, Cancer Cell, and the Journal of Clinical Oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Tumor-Infiltrating Lymphocytes as Prognostic Biomarkers in Breast Cancer
Pioneered the clinical quantification and prognostic significance of TILs in TNBC and HER2+ breast cancer, demonstrating in large retrospective and prospective datasets that each 10% increment in stromal TIL percentage is associated with a significant improvement in distant disease-free and overall survival, enabling TIL scoring to become a standard pathology reporting element.
Immune Predictors of Chemotherapy Response in Early TNBC
Demonstrated that high TIL levels in primary TNBC tumors predict pathological complete response to neoadjuvant chemotherapy, and that residual TILs post-neoadjuvant treatment remain prognostically relevant, identifying TILs as dual biomarkers of both chemosensitivity and post-treatment immune surveillance in early-stage disease.
Translational Immunogenomics Supporting PD-1/PD-L1 Blockade in TNBC
Led translational substudy analyses for the IMpassion130 and KEYNOTE-522 trials, characterizing the relationship between TIL density, PD-L1 expression, immune gene signatures, and clinical benefit from atezolizumab or pembrolizumab, helping define the molecular subgroups most likely to benefit from immune checkpoint inhibition in TNBC.
International TILs Working Group and Standardization of TIL Assessment
Co-founded and leads the International Immuno-Oncology Biomarker Working Group on Breast Cancer, which developed and published internationally adopted guidelines for standardized TIL assessment in breast cancer pathology, enabling multi-center comparability of TIL data across clinical trials and routine diagnostic practice.
Representative Works 代表性著作
Tumor-infiltrating lymphocytes and prognosis in breast cancer: A pooled individual patient analysis (International TILs Working Group)
The Lancet Oncology (2016)
Pooled analysis of 9,500 patients demonstrating that TIL levels are independently prognostic in TNBC and HER2+ breast cancer, establishing TILs as the first immune biomarker validated across multiple early breast cancer trials.
Prognostic significance of tumor-infiltrating lymphocytes in patients with metastatic HER2+ breast cancer
Journal of Clinical Oncology (2014)
Demonstrated for the first time that TIL levels in metastatic HER2+ breast cancer biopsies are independently prognostic, with high TILs associated with superior survival on trastuzumab-based therapy.
Association of stromal tumor-infiltrating lymphocytes with improved outcomes in triple-negative and HER2-positive breast cancer treated with neoadjuvant chemotherapy
JAMA Oncology (2018)
Large multicenter study confirming TILs as predictors of pCR after neoadjuvant chemotherapy in TNBC and HER2+ breast cancer, with post-treatment residual TILs remaining prognostically informative.
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer (IMpassion130): Updated overall survival results
Annals of Oncology (2020)
Updated OS analysis of IMpassion130 with translational biomarker data confirming PD-L1 immune cell status and TIL density as predictors of atezolizumab benefit in first-line metastatic TNBC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 谢伦·洛伊 的研究动态
Follow Sherene Loi's research updates
留下邮箱，当我们发布与 Sherene Loi（Peter MacCallum Cancer Centre / The University of Melbourne）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment